MYTOLAC Treatment and the NAVIGATION Patient Support Program To begin treatment with MYTOLAC, the patient must be enrolled in the NAVIGATION patient support program by means of an enrollment form, completed with the patient’s consent, to allow the program to communicate directly with them. Enrollment can be completed, with the patient’s authorization, by the medication … Read more
TECVAYLI (Teclistamab) is now indicated in combination with daratumumab for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
VERZENIOMD (abemaciclib) (tablets) is a CDK4/6 inhibitor indicated for the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer:
Launch ofthe patient support program for the FLAURA2 indication, opening on October 1, 2025. The indication covered by this program: TAGRISSO in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced (not amenable to curative treatment) or metastatic NSCLC carrying a deletion in exon 19 or a substitution mutation … Read more
Scemblix® (asciminib) is now available for patients with newly diagnosed and previously treated chronic myeloid leukemia (CML) . Scemblix® is the first drug to demonstrate superior efficacy and a favorable safety and tolerability profile in a Phase III trial, compared to all standards of care. Contact Novartis for more information on the patient support program.